Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization

Circulation

Volumn 103, Issue 7, 2001, Pages 926-933

  Crisby, Milita ^a   Nordin Fredriksson, Gunilla ^b   Shah, Prediman K ^c,d   Yano, Juliana ^c   Zhu, Jenny ^c   Nilsson, Jan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Inflammation; Plaque; Pravastatin

Indexed keywords

ANTILIPEMIC AGENT; COLLAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CELL DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; INFLAMMATION; LIPID OXIDATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035916233     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.7.926     Document Type: Article

References (43)

1. Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin survival Study (4S)
3. Lipid lowering therapy for patients with or at risk for coronary artery disease
4. Prevention of coronary heart disease in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
5. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: New evidence, implications and outstanding issues
6. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
7. Effects of simvastatin on coronary atheroma: The Multicenter Anti-Atheroma Study (MAAS)
8. Atherosclerosis regression, plaque disruption, and cardiovascular events: A rationale for lipid lowering in coronary artery disease
9. Role of inflammation and metalloproteinases in plaque disruption and thrombosis
10. Plaque fissuring: The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina
11. Molecular basis of the acute coronary syndromes
12. Plaque disruption and thrombosis: Potential role of inflammation and infection
13. Reduction of serum cholesterol levels alters composition of atherosclerotic plaques
14. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
15. Pravastatin has cholesterol-lowering independent effects on the artery wall of monkey arteries
16. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
17. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis
18. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man
19. Protein measurement with the Folin phenol reagent
20. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly
21. Membrane type I metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory mediators
22. Kuopio Atherosclerosis Prevention Study (KAPS): A population-based primary preventive trial of the effect of LDL lowering on atherosclerosis progression in carotid and femoral arteries
23. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
24. The role of oxidized low-density lipoprotein in atherogenesis
25. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages
26. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
27. Coronary plaque disruption
28. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture
29. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
30. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
31. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture
32. Plaque disruption and coronary thrombosis: New insight into pathogenesis and prevention
33. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
34. Association of coronary plaque rupture and atherosclerotic inflammation
35. Inflammation, pravastatin, and the risk for coronary events after myocardial infarction in patients with average cholesterol levels
36. Long-term effects of pravastatin on plasma concentration of C-reactive protein
37. Inhibition of proinflammatory cytokine production by pravastatin
38. The smooth muscle cell: Sinner or saint in restenosis and the coronary syndromes?
39. Cell death in atherosclerotic plaques involves both oncosis and apoptosis
40. Direct effects of statins on the vascular wall
41. Collagen types I and III, collagen content. GAGs and mechanical strength of human atherosclerotic plaque caps: Span-wise variations
42. Atherosclerotic plaque caps are locally weakened when macrophages density is increased
43. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques